Novel therapies of non-revascularizing peripheral arterial occlusive disease: therapeutic angiogenesis;Nuevos tratamientos de la enfermedad arterial periférica oclusiva no revascularizable: angiogenia terapéutica

Medicina Clinica

Volumn 131, Issue 17, 2008, Pages 665-669

  Lara Hernández, Raúl ^a   Lozano Vilardell, Pascual ^b   Cordobés Gual, Jordi ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Cell therapy; Critical limb ischemia; Gene therapy; Peripheral arterial occlusive disease; Progenitor endothelial cells; Therapeutic angiogenesis

Indexed keywords

RECOMBINANT PROTEIN; ANGIOGENIC FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; HUMAN; INTERMITTENT CLAUDICATION; LIMB AMPUTATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; ADULT; AMPUTATION; BUERGER DISEASE; COLLATERAL CIRCULATION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; EXERCISE; GENE THERAPY; ISCHEMIA; LEG; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; VASCULARIZATION;

ADULT; AMPUTATION; ANGIOGENESIS INDUCING AGENTS; ARTERIAL OCCLUSIVE DISEASES; COLLATERAL CIRCULATION; CONTROLLED CLINICAL TRIALS AS TOPIC; EXERCISE; GENE THERAPY; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; LEG; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; STEM CELL TRANSPLANTATION; THROMBOANGIITIS OBLITERANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60849122257     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13128727     Document Type: Review

References (42)

1. Dormandy J., Mahir M., Ascady G., Balsano F., De Leeuw P., Blombery P., et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg 30 (1989) 50-57
2. Lozano-Vilardell P., Corominas-Roura C., Gómez-Ruiz F.T., Manuel-Rimbau E., and Juliá-Montoya J. Evolución natural de la isquemia crítica de los miembros inferiores. Angiología 55 Supl 1 (2003) 38-46
3. Inter-Society Consensus for the Management of Peripheral Arterial Disease. (TASC II). Eur J Vasc Endovasc Surg. 2007;33:S5-S75.
4. Wolfe J.H., and Wyatt M.G. Critical and subcritical ischaemia. Eur J Vasc Endovasc Surg 13 (1997) 578-582
5. Rowlands T.E., and Donnelly R. Medical therapy for intermittent claudication. Eur J Endovasc Surg 34 (2007) 314-321
6. Risau W., Sariola H., Zerwes H.G., Sasse J., Ekblom P., Kemler R., et al. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development 102 (1988) 471-478
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
8. Oren M., Tepper B.A., Galiano R.D., Kalka C., and Gurtner G.C. Endothelial progenitor cells: the promise of vascular stem cells for plastic surgery. Plastic Reconstructive Surgery 111 (2003) 846-854
9. Collinson D.J., and Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation?. Eur J Vasc Endovasc Surg 28 (2004) 9-23
10. Yoshida W.B. Angiogenesis, arteriogenesis and vasculogenesis: treatment of the future for lower limb critical ischemia?. Braz Vasc J 4 (2005) 209-211
11. Rajagopalan S., Mohler E., Lederman R.J., Saucedo J., Mendelsohn F.O., Olin J., et al. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am Heart J 145 (2003) 1114-1118
12. Baffour R., Berman J., Garb J., Rhee S., Kaufman J., and Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant bFGF in a rat model of acute lower limb ischaemia: dose response effect of bFGF. J Vasc Surg 2 (1992) 181-191
13. Morishita R., Nakamura S., Hayashi S., Taniyama Y., Moriguchi A., Nagano T., et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in a rabbit hind limb ischaemia model as cytokine supplement therapy. Hypertension 33 (1999) 1379-1384
14. Henry T., Annex B., McKendall G., Azrin M., López J., Giordano F., et al. The VIVA Trial: VEGF in Ischaemia for Vascular Angiogenesis. Circulation 107 (2003) 1359-1365
15. Lederman R.J., Mendelsohn F., Anderson R.D., Saucedo J.F., and Hermiller J.B. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359 (2002) 2053-2058
16. Vale P., Isner J., and Rosenfield K. Therapeutic angiogenesis in critical limb and myocardial ischaemia. J Interven Cardiol 14 (2001) 511-528
17. Hedman M., Hartikainen J., Sylvanne M., Stjernvall J., Hedman A., Kivela A., et al. Safety and feasibility of catheter-based local intracoronary VEGF gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischaemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107 (2003) 2677-2683
18. Isner J.M., Baumgartner I., Rauh G., Schainfeld R., Blair R., Manor O., et al. Treatment of thromboangeitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 28 (1998) 964-975
19. Shyu K.G., Chang H., Wang B.W., and Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischaemia. Am J Med 114 (2003) 85-92
20. Rajalopalan S., Mohler E.R., Lederman R.J., Mendelsohn F.O., Saucedo J.F., Goldman C.K., et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double- blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108 (2003) 1933-1938
21. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 282 (1998) 1145-1147
22. Weissman I.L., and Baltimore D. Disappearing stem cells, disappearing science. Science 292 (2001) 601
23. Flax J.D., Aurora S., Yang C., Simonin C., Wills A.M., Billinghurst L.L., et al. Engraftable human neural stem cells respond to developmental cues, replace neurons and express foreign genes. Nat Biotechnol 16 (1998) 1033-1039
24. Kalka C., Masuda H., Takahashi T., Kalka-Moll W.M., Silver M., Keamey M., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 97 (2000) 3422-3427
25. Clarke D.L., Johansson C.B., Wilbertz J., Veress B., Nilsson E., Karlström H., et al. Generalized potential of adult neural stem cells. Science 288 (2000) 1660-1663
26. Gage F.H. Mammalian neural stem cells. Science 287 (2000) 1433-1827
27. To L.B., Haylock D.N., Simmons P.J., and Juttner C.A. The biology and clinical uses of blood stem cells. Blood 89 (1997) 2233-2258
28. Jones P.H., and Watt F.M. Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 73 (1993) 713-724
29. Asahara T., Murohara T., Sullivan E., Silver M., Van der Zee R., Li T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
30. Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., et al. Bone marrow cells regenerate infarcted myocardium. Nature 410 (2001) 701-705
31. Perin E.C., Dohmann H.F., Borojevic R., Silva S.A., Sousa A.L., Mesquita C.T., et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107 (2003) 2294-2302
32. Rauscher F.M., Goldschmidt-Clermont P.J., Davis B.H., Wang T., Gregg D., Ramaswami P., et al. Aging progenitor cell exhaustion, and atherosclerosis. Circulation 108 (2003) 457-463
33. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A.M., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
34. Collinson D.J., and Donnelly R. Therapeutic angiogenenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation?. Eur J Vasc Endovasc Surg 28 (2004) 9-23
35. Zammaretti P., and Zisch A.H. Adult endothelial progenitor cells. Renewing vasculature. Int J Biochem Cell Biol 37 (2005) 493-503
36. Simons M., and Angiogenesis. Where do we stand now?. Circulation 111 (2005) 1556-1566
37. Yuyama E.T., Matsubara H., Murohara T., Ikeda U., Shintani S., Masaki H., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial. Lancet 360 (2002) 427-435
38. Kawamura A., Horie T., Tsuda I., Ikeda A., Egawa H., Imamura E., et al. Prevention of limb amputation in patients with limbs ulcers by autologous peripheral blood mononuclear cell implantation. Ther Apher Dial 9 (2005) 59-63
39. Huang P.P., Li S.Z., Han M.Z., Xiao Z.J., Yang R.C., Qiu L.G., et al. Autologous transplantation of peripheral blood stem cells as an effective therapeutic approachfor severe arteriosclerosis obliterans of lower extremities. Thromb Haemost 91 (2004) 606-609
40. Durdu S., Akar A.R., Arat M., Sancak T., Eren N.T., and Ozyurda U. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg 44 (2006) 732-739
41. Kawamura A., Horie T., Tsuda I., Abe Y., Yamada M., Egawa H., et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood item cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs 9 (2006) 226-233
42. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A.M., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 (2001) 1-7